Health news today spans both scientific progress and accountability. In a major industry move, GSK agreed to buy cancer drug developer Nuvalent for $10.6 billion, one of its biggest deals in years, as it rebuilds an oncology portfolio with a particular eye on lung cancer treatments. Regulators also delivered a long-awaited consumer health breakthrough, with the FDA approving bemotrizinol as the first new over-the-counter sunscreen active ingredient in roughly a quarter century, expanding options for UVA and UVB protection in the U.S. At the same time, the Trump administration warned more than 500 hospitals that they could face fines if they fail to comply with federal price-transparency rules meant to help patients understand medical costs. Taken together, the day’s developments reflect a health sector balancing innovation, corporate consolidation, and mounting pressure for greater public access—both to better treatments and to clearer information.